Abstract

In 2021, during a drug-related death crisis in the UK, the Government published its ten-year drugs strategy. This article, written in collaboration with the Faculty of Public Health and the Association of Directors of Public Health, assesses whether this Strategy is evidence-based and consistent with international calls to promote public health approaches to drugs, which put ‘people, health and human rights at the centre’. Elements of the Strategy are welcome, including the promise of significant funding for drug treatment services, the effects of which will depend on how it is utilized by services and local commissioners and whether it is sustained. However, unevidenced and harmful measures to deter drug use by means of punishment continue to be promoted, which will have deleterious impacts on people who use drugs. An effective public health approach to drugs should tackle population-level risk factors, which may predispose to harmful patterns of drug use, including adverse childhood experiences and socioeconomic deprivation, and institute evidence-based measures to mitigate drug-related harm. This would likely be more effective, and just, than the continuation of policies rooted in enforcement. A more dramatic re-orientation of UK drug policy than that offered by the Strategy is overdue.

Introduction

In 2021, the UK Government published its 10-year drugs strategy, From Harm to Hope1 (hereafter referred to as ‘the Strategy’) following Dame Black’s Independent Review of Drugs.2 This is during a period of escalating drug-related deaths in the UK3–5 surpassing the rates of many countries.6 The following analysis, undertaken with the Faculty of Public Health and Association of Directors of Public Health, assesses whether the Strategy is evidence-based and consistent with the call from the highest coordination forum of the United Nations (UN) to ensure drug strategies promote public health and human rights.7 The Strategy is structured under three strategic priorities: to ‘Break drug supply chains’, ‘Deliver a world-class treatment and recovery system’, and ‘Achieve a generational shift in demand for drugs’. This article discusses drug-related harm in the UK, the Strategy’s three pillars, and highlights missing elements of policy.

Drug-related harm in the UK

‘Drug-related harm’ encompasses the negative health and social impacts associated with illicit drug use, and drug market involvement. As acknowledged by the Strategy, and the Black Review,2 which preceded it, current approaches have not effectively reduced many of these harms. Various health and social issues including socioeconomic deprivation, mental and physical health problems, stigma, trauma and homelessness may both predispose to and be exacerbated by drug dependence.8–10

Amongst the health harms related to drug use, drug-related deaths provide the most obvious metric. Between 2010 and 2019, age standardized drug-related mortality rates increased in Scotland by 171% (from 90 to 244 per million)3; Northern Ireland by 149% (from 35 to 87 per million)4; and England and Wales by 61% (from 31 to 49 per million).5 There are likely multiple reasons for these increases.2,11 A common argument is that deaths increased because people with drug dependencies are older, with comorbidities increasing overdose risk. Two recent studies, however, demonstrated ageing alone does not explain the increase.12,13 Other potential contributory factors include: (i) increasing polydrug use, with the risk of opioid overdose increasing with concomitant benzodiazepine, gabapentinoid, and alcohol use14–17; (ii) increasing homelessness and incarceration, which are associated with mortality risk, and human immunodeficiency virus (HIV) and hepatitis C (HCV) transmission9,10,18; (iii) changing patterns of socioeconomic deprivation, which is strongly associated with drug-related harm19–21 and (iv) cuts to services that protect against all-cause and drug-related mortality.2,21,22

The Strategy makes some unsupported assumptions about the relationship between drugs and social problems. It suggests that drugs ‘blight’ neighbourhoods, stopping them from reaching their potential, implying drugs cause socioeconomic deprivation as opposed to the latter creating conditions in which drug markets flourish. Socioeconomic deprivation and adverse childhood experiences are inter-related23 with both associated with harmful patterns of drug use,19,20,24 Furthermore, disinvestment in health and social services in socioeconomically deprived areas since 2010 may have contributed to increasing harm.22

Drug-related harms to third parties include acquisitive crime and drug-related violence. However, in some instances the Strategy exaggerates the causative relationship between drugs and crime. For example, it states drugs ‘contribute’ to almost half of all homicides, seemingly implying causation. In 2020, 48% of homicides were in some way related to drugs—in most cases, the victim or perpetrator was known to use or deal drugs, sometimes recently.25 In a small proportion of cases, motives were related to obtaining drugs or drug proceeds,25 but for the most part, it is not clear that drugs caused the homicides, and in no cases is it clear stricter drug controls would have prevented them.

Breaking drug supply chains

The first pillar of the strategy aims to: reduce drug availability by targeting supply chains, including international, wholesale and retail providers, with a particular focus on ‘county lines dealing’ (when drugs are transported from cities to other areas, and sold using a mobile phone ‘line’).

There is some evidence that limiting the supply of a drug increases its purity adjusted price,26 which can reduce demand for that drug,27 thereby reducing hospital attendances and overdoses related to its use.28 There are, however, three issues with enforcement-led efforts to reduce drug supply.

First, there is limited evidence of their effectiveness. The Government has highlighted there is a lack of relevant evaluative research,29 and available evidence does not suggest that arresting dealers or seizing drugs has a long-term impact on supply.30 Internationally, there have been some isolated reductions in drug supply, for example, after global market disruption interrupted heroin supply in Australia in 200031 and Western Europe in 201032; and controls on precursor chemicals in the USA in 1989 and 2006 impacted cocaine availability.33 These reductions were, however, temporary, and it is not clear what caused them when other efforts have not had the same impact. Despite recent seizures, global production and purity of drugs continues to increase34 and the UK has amongst the cheapest heroin and cocaine in Europe.35

Second, there is limited understanding of how restricting the supply of certain drugs affects the supply of, demand for, and harm related to other drugs. For example, during ‘droughts’ of specific drugs, people may use adulterated drugs, alternative drugs, or resort to polydrug use.36–39

Third, enforcement may have unintended consequences on the drug market and people who use drugs, leading to increased harm. Focussing on the most violent and exploitative forms of supply, such as those associated with county lines dealing40 may shape the market to adopt less harmful practices.41,42 However, as the Black Review highlighted,2 arresting suppliers can create conditions that favour competition, promoting innovation and violence.41–51

Delivering a world-class treatment and recovery system

The second pillar of the Strategy aims to: rebuild treatment services following significant disinvestment; promote integration of drug treatment, health and criminal justice services; and improve employment and accommodation opportunities.

Additional drug treatment funding promised by the Strategy is welcome; however, this follows years of sustained disinvestment,2 associated with reductions in numbers of people in treatment,52 and an increase in the proportion of people using opioids and crack cocaine not engaged with services.53 Furthermore, drugs workers have experienced increasing caseloads and greater administrative responsibilities, sometimes limiting their capacity to provide psychosocial interventions.54

The Strategy suggests ‘recovery from drug addiction’ is a key aspect of its approach. As the UK Government Recovery Champion highlights, recovery and harm reduction should not be considered as opposing approaches, and the full range of evidence-based interventions should be provided.55 Opioid agonist therapy (OAT—treatment of opioid dependence with methadone or buprenorphine) reduces the risks of all-cause mortality, overdose, suicide, self-harm, HIV and HCV, improves quality of life9,56–61 and duration of OAT improves survival.62–65 Whilst modelling demonstrates comprehensive OAT and harm reduction programmes reduce drug-related mortality,66–68 this is dependent on retention in treatment, which should be a key indicator. Focusing on treatment completion may incentivise premature OAT cessation, limiting treatment benefits and the impact of additional funding.

Increased funding and targeted commissioning could allow the introduction of innovative interventions, including drug checking and diamorphine-assisted treatment—neither of which the Strategy mentions. No intervention alone will avert the drug-related death crisis, but in combination with wider treatment systems, these evidence-based interventions could have beneficial impacts on patterns of harm.69–72 Local areas may need additional funding and technical support to commission diamorphine-assisted treatment, which is more expensive than oral OAT.73 These costs, however, are compensated by greater savings to wider services, including related to reductions in acquisitive crime.73 Drug checking, on the other hand, is expanding, as the UK’s first regular Home Office licensed, local authority funded drug checking service launches in Bristol.74

Despite their relevance, the Strategy does not mention HCV and HIV prevention. An estimated 89% of people infected with HCV in the UK have injected drugs75 and a recent outbreak of HIV occurred amongst people who inject drugs in Glasgow.76 The UK is a leader in providing HCV treatment for people who inject drugs, with clear reductions in chronic infections and liver-related deaths.12,77–80 However, achieving the World Health Organization (WHO) target of ‘eliminating HCV as a public health problem’75 will depend on preventing reinfection, with HCV infection a critical indicator for assessing the success of drug treatment and harm reduction systems.81

People with drug dependencies often have co-occurring health problems. People in drug treatment are getting older, and more deaths are caused by long-term conditions than overdoses.12,82 Office for Health Improvement and Disparities data suggest 63% of people starting drug treatment have a mental health need53 and people with substance dependence are at greater risk of suicide.83 A recent study demonstrated that one in fourteen opioid-related deaths in England occur amongst people recently discharged from hospital,84 highlighting the need to improve integration between healthcare and drug treatment services. Drug services will need to recruit more clinically trained staff to identify and manage co-occurring health issues, which will be challenging as the workforce has been depleted by disinvestment. Furthermore, hospital care for people with drug dependence requires improvement. Stigmatizing attitudes towards people who use drugs and fear of opioid withdrawal are key barriers to healthcare access,85–87 underpinned by hospital policies that create significant procedural barriers to providing OAT.88

Drug-related harm remains a key issue in prison, with overdose risk substantially elevated in the month following release89–91 and incarceration a risk factor for HIV and HCV.18 Prison OAT reduces mortality and drug use in prison and critically also mortality following release.92,93 The Strategy’s proposed zero-tolerance approach to drugs is inconsistent with the Inspectorate of Prisons acknowledgement of the importance of harm reduction strategies in prisons.94 Proposed alternatives to prison OAT, including detoxification, are experimental, and it is necessary to demonstrate they do not increase drug-related deaths (during and after incarceration) compared to OAT. Evaluations of previous Drug Recovery Wings, which utilized abstinence and harm reduction-based approaches, highlighted potential benefits but identified challenges, particularly related to limited support on release.95 The Strategy recognizes the need for improved inter-agency coordination during and following incarceration, however recommendations from the Advisory Council on the Misuse of Drugs (ACMD) to improve custody-community transitions have not been realized.96

Achieving a generational shift in the demand for drugs

The third pillar of the Strategy aims to: reduce demand for drugs by applying ‘tougher and more meaningful consequences’ to deter use, delivering education programmes in schools and supporting at risk families.

The assumption that the threat of punishment will reduce demand is not supported by evidence, with no clear relationship between the stringency of drug laws and drug use prevalence.97–101 The Home Office previously concluded ‘levels of drug use are influenced by factors more complex and nuanced than legislation and enforcement alone’.102 These may include socioeconomic deprivation19 and adverse childhood experiences24; factors that may be exacerbated by the health and social harms associated with contact with the criminal justice system.103 Additionally, the stigma associated with punitive policies may deter people with drug dependence from seeking support.104

The Strategy’s proposed ‘tough consequences out of court disposal schemes’ provide an opportunity to divert people from the criminal justice system. Available evidence tentatively suggests diversion schemes reduce re-offending more effectively and cost-effectively than criminal sanctions.105–108 However, there is limited research evaluating their impacts on drug-related harms109 and existing diversion schemes vary in approach and ethos. Whilst diversion schemes may mitigate some of the harms associated with criminal sanctions, most are still designed to negatively impact people who use drugs, which may exacerbate the issues predisposing to harmful use.

The Government’s subsequent White Paper, SWIFT, CERTAIN, TOUGH (in consultation), proposes escalating consequences for drug possession including: mandatory drugs awareness courses, random drug testing (and expansion of drugs tested for on arrest), passport and driving licence confiscation, wearable drug monitors and exclusion orders prohibiting attendance of particular venues.110 These proposals raise significant concerns. Mandatory drugs awareness courses will require payment, with non-attendance and non-payment punished with fines or criminal charges, placing an inequitable burden on the socioeconomically deprived, who are the most likely to be caught. Passport and driving license confiscations may affect employment prospects and will disproportionately impact the rights of people who use drugs. The intention to ensure ‘more people face consequences of their use’ with expanded drug testing is likely to ‘widen the net’, with more people receiving punishments that may escalate to criminal sanctions with questionable justification. Furthermore, the Strategy implies people could be coerced into drug treatment, contravening human rights and medical ethics norms,111 with limited evidence that coerced treatment reduces future drug use.111,112

It remains to be seen how proposed schemes will contribute to the stigma faced by people who use drugs, and whether they will reproduce the ethnic and socioeconomic disparities apparent in current enforcement. People who are black are nearly nine times more likely to be stopped and searched for drugs than people who are white and are more likely to be arrested, prosecuted, and sentenced to immediate custody.113 Whilst the Strategy recognizes the problem of disproportionate policing, plans to expand punishments that inequitably impact the socioeconomically deprived do not align with efforts to reduce inequalities and ‘level up’ communities.114

What’s missing?

The Strategy states it is taking a new approach; however, most elements are a continuation of former approaches proposed in the context of existing legislation, rather than allowing for legislative reform to decriminalize the possession of drugs and facilitate innovative interventions.

The Strategy suggests that decriminalization risks increasing drug use; however, this is not supported by evidence.97–101 Whilst criminalization has no clear benefits, it causes significant harm to people who use drugs.115 Since the Misuse of Drugs Act 1971 was introduced, more than three million criminal records have been generated for drugs offences.116 In 2017, 60% of prosecutions for drug offences in England and Wales were for possession rather than supply, including 36% for the possession of cannabis.113 In the UK, decriminalization has been recommended by bodies including the 2019 Health and Social Care Committee on Drug Policy117; the Royal College of Physicians118; the Royal Society of Public Health and the Faculty of Public Health.119 Internationally, over 30 countries have some degree of decriminalization,101 and it has been recommended by the highest coordination forum of the UN, comprising the Executive Heads of organizations including the WHO and the UN Office for Drugs and Crime.7

The Government has resisted the introduction of overdose prevention centres,120 despite promising evidence they could reduce drug-related deaths and engage the most marginalized with services.70,121 The introduction of pilot sites has been recommended by numerous health, academic and third sector organizations,122,123 the ACMD,21 the 2019 Health and Social Care Committee on Drugs Policy117 and the Scottish Drug Deaths Taskforce.124 Although overdose prevention centres may be provided in the UK with agreement from local agencies,125 legislative change would facilitate pilots, allowing evaluations of their effectiveness and cost-effectiveness.120 Currently, legislation also creates barriers to providing smoking paraphernalia to engage people who use crack cocaine with services,126 as is the case in other countries.127

There was no opportunity for public consultation in the Strategy’s development. For other health and social policies, research and commissioning, the views of the public are included as a matter of priority.128,129 Generally, the views of people who use drugs, who entreat that there should be ‘nothing about us without us’,130 have not been adequately considered when developing drugs strategies.131 Communities of people who use drugs, and UN agencies, have highlighted human rights implications, including the right to non-discrimination, should be a primary consideration in developing drug strategies.7,132,133 The Strategy does not mention human rights, and punitive policies and restrictions on access to harm reduction programmes are often at odds with human rights norms.115,134

Stigma related to drug use, including that propagated by the language used to describe people who use drugs,135 creates barriers to seeking support.104 The Strategy identifies the need to reduce stigma. However, the Government has also suggested that stigma is a valued means to deter drug use initiation.136 Elements of the Strategy could be seen as promoting stigma, for example referring to acquisitive crime in terms of’[t]he innocent families whose homes are broken into by addicts seeking to feed their habits’.1 Independent anti-stigma campaigns have been launched,137,138 but the evidence for their effectiveness is limited,139 as sources of stigma are complex,140 and efforts would need to translate into policy and practice to have meaningful impact.

Conclusion

There are significant inconsistencies between the Strategy and the call from the highest coordination forum of the UN to promote public health approaches to drugs, putting ‘people, health and human rights at the centre’.7 A public health approach should tackle upstream factors predisposing to harmful drug use alongside many other health and social disadvantages. Whilst promised investment in drug treatment is welcome and likely to be beneficial, this alone will not solve the drug-related death crisis. Realizing the potential benefits of additional funding and achieving the ambition to develop a ‘world class treatment and recovery system’ will depend on addressing fundamental flaws in the Strategy’s approach. Furthermore, an effective public health strategy should reflect best evidence. Whilst the Strategy states evidence is ‘at the heart’ of its approach, this is not always the case as it continues to promote un-evidenced and harmful measures to deter drug use with punishment.

We believe a public health approach to drugs would be more effective than policies rooted in criminalization and enforcement. Framing drug use as something deserving of punishment promotes stigmatizing attitudes, which pose a barrier to accessing support and approaches that do not adequately consider the views and human rights of people who use drugs. For more than fifty years, this has failed to effect improvements and a more dramatic re-orientation of the UK response to drugs is overdue.

Acknowledgements

This article was written in collaboration with the Faculty of Public Health and the Association of Directors of Public Health.

Conflict of Interests

AH is a volunteer harm reduction adviser for the Loop—a not-for-profit drug checking service provider. AS is a trustee for Harm Reduction International. DS is a volunteer for the Loop. JN is a Trustee at Cranstoun, a third sector drug and alcohol treatment provider. JS works as a pharmacist prescriber with a third sector drug and alcohol treatment provider. LR is Director of Corporate Services for the Hepatitis C Trust. ED is the UK Government Recovery Champion. FM is the Director of the Loop.

Funding

No funding supported this research.

Data availability

No new data were generated or analyzed in support of this research.

References

1.

HM Government
.
From harm to hope - A 10-year drugs plan to cut crime and save lives
.
2021
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043484/From_harm_to_hope_PDF.pdf (
26 May 2021, date last accessed
).

2.

Home Office and Department of Health and Social Care
.
Independent review of drugs by Professor Dame Carol Black
.
2021
. https://www.gov.uk/government/collections/independent-review-of-drugs-by-professor-dame-carol-black (
26 May 2022, date last accessed
).

3.

National Records of Scotland
.
Drug-related Deaths in Scotland in 2020
.
2021
. https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland/2020  
(15 April 2022, date last accessed)
.

4.

Northern Ireland Statistics and Research Agency
.
Drug-Related Deaths
.
2022
. https://www.nisra.gov.uk/statistics/cause-death/drug-related-deaths (
15 April 2022, date last accessed
).

5.

Office for National Statistics
.
Deaths related to drug poisoning in England and Wales: 2020 registrations
.
2021
. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2020 (
15 April 2022, date last accessed
).

6.

European Monitoring Centre for Drugs and Drug Addiction
.
Drug-related deaths and mortality in Europe - Update from the EMCDDA expert network
.
2021
. https://www.emcdda.europa.eu/system/files/publications/13762/TD0221591ENN.pdf (
15 April 2022, date last accessed
).

7.

United Nations Chief Executives Board for Coordination
.
United Nations system common position supporting the implementation of the international drug control policy through effective inter-agency collaboration
.
2019
. https://unsceb.org/sites/default/files/2021-01/2018%20Nov%20-%20UN%20system%20common%20position%20on%20drug%20policy.pdf (
24 May 2022, date last accessed
).

8.

Strang
 
J
,
Volkow
 
ND
,
Degenhardt
 
L
 et al.  
Opioid use disorder
.
Nat Rev Dis Primers
 
2020
;
6
(
1
)::1–28.

9.

Degenhardt
 
L
,
Grebely
 
J
,
Stone
 
J
 et al.  
Global patterns of opioid use and dependence: harms to populations, interventions, and future action
.
Lancet
 
2019
;
394
(
10208
):
1560
79
.

10.

Stone
 
J
,
Artenie
 
A
,
Hickman
 
M
 et al.  
The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study
.
Lancet Public Health
 
2022
;
7
(
2
):
136
45
.

11.

Public Health England
.
Understanding and preventing drug-related deaths
.
2016
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/669308/Understanding_and_preventing_drug_related_deaths_report.pdf (
16 March 2022, date last accessed
).

12.

Lewer
 
D
,
Brothers
 
TD
,
Van Hest
 
N
 et al.  
Causes of death among people who used illicit opioids in England, 2001–18: a matched cohort study
.
Public Health
 
2022
;
7
(
2
):
e126
35
.

13.

McDonald
 
SA
,
McAuley
 
A
,
Hickman
 
M
 et al.  
Increasing drug-related mortality rates over the last decade in Scotland are not just due to an ageing cohort: A retrospective longitudinal cohort study
.
Foreign Policy
 
2021
;
96
:
103286
.

14.

Macleod
 
J
,
Steer
 
C
,
Tilling
 
K
 et al.  
Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records
.
PLoS Med
 
2019
;
16
(
11
):
e1002965
.

15.

McAuley
 
A
,
Matheson
 
C
,
Robertson
 
JR
.
From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic
.
Int J Drug Policy
 
2022
;
100
:
103512
.

16.

Lyndon
 
A
,
Matheson
 
C
,
Robertson
 
JR
.
Risk to heroin users of polydrug use of pregabalin or gabapentin
.
Addiction
 
2017
;
112
(
9
):
1580
9
.

17.

Hill
 
R
,
Lyndon
 
A
,
Withey
 
S
 et al.  
Ethanol reversal of tolerance to the respiratory depressant effects of morphine
.
Neuropsychopharmacology
 
2016
;
41
(
3
):
762
73
.

18.

Stone
 
J
,
Fraser
 
H
,
Lim
 
AG
 et al.  
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
.
Lancet Infect Dis
 
2018
;
18
(
12
):
1397
409
.

19.

Marmot
 
M
.
Fair Society, Healthy Lives - The Marmot Review
.
Institute of Health Equity
 
2010
. http://www.instituteofhealthequity.org/resources-reports/fair-society-healthy-lives-the-marmot-review/fair-society-healthy-lives-full-report-pdf.pdf  
19 February 2022, date last accessed
.

20.

Kontopantelis
 
E
,
Buchan
 
I
,
Webb
 
RT
 et al.  
Disparities in mortality among 25–44-year-olds in England: a longitudinal, population-based study
.
Lancet Public Health
 
2018
;
3
(
12
):
567
75
.

21.

Advisory Council on the Misuse of Drugs
.
Reducing Opioid-Related Deaths in the UK
.
2016
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/576560/ACMD-Drug-Related-Deaths-Report-161212.pdf (
6 September 2021, date last accessed
).

22.

Marmot
 
M
,
Allen
 
J
,
Boyce
 
T
,
Goldblatt
 
P
,
Morrison
 
J
.
Health Equity in England: The Marmot Review 10 Years On
.
2020
. https://www.instituteofhealthequity.org/resources-reports/marmot-review-10-years-on/the-marmot-review-10-years-on-full-report.pdf (
5 May 2022, date last accessed
).

23.

Lewer
 
D
,
King
 
E
,
Bramley
 
G
 et al.  
The ACE Index: mapping childhood adversity in England
.
J Public Health
 
2020
;
42
(
4
):
487
95
.

24.

Public Health Wales
.
Welsh Adverse Childhood Experiences (ACE) Study
.
2015
. http://researchonline.ljmu.ac.uk/2648/1/ACE%20Report%20FINAL%20%28E%29.pdf (
26 May 2022, date last accessed
).

25.

Office for National Statistics
.
Homicide in England and Wales: Year Ending March 2020
.
2021
. https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/homicideinenglandandwales/yearendingmarch2020#drug-and-alcohol-related-homicides (
19 April 2022, date last accessed
).

26.

MacCoun
 
RJ
,
Reuter
 
P
.
Drug War Heresies: Learning from Other Vices. Times & Places
.
Cambridge
:
Cambridge University Press
,
2001
.

27.

Payne
 
J
,
Manning
 
M
,
Fleming
 
C
,
Pham
 
H-T
.
Trends & issues in crime and criminal justice - The price elasticity of demand for illicit drugs: A systematic review
.
2020
. https://www.aic.gov.au/sites/default/files/2020-10/ti606_price_elasticity_of_demand_for_illicit_drugs.pdf (
28 March 2022, date last accessed
).

28.

Hughes
 
C
,
Hulme
 
S
,
Ritter
 
A
.
The relationship between drug price and purity and population level harm
.
2020
. https://www.aic.gov.au/sites/default/files/2020-07/ti598_relationship_between_drug_price_and_purity.pdf (
13 April 2022, date last accessed
).

29.

HM Government
.
An evaluation of the Government's Drug Strategy 2010
.
2017
. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/628100/Drug_Strategy_Evaluation.PDF (
14 March 2022, date last accessed
).

30.

Eggins
 
E
,
Hine
 
L
,
Higginson
 
A
,
Mazerolle
 
L
.
The impact of arrest and seizure on drug crime and harms: A systematic review
.
Trends Issues Crime Crim Justice
 
2020
. http://www.aic.gov.au/sites/default/files/2020-09/ti602_impact_of_arrest_and_seizure_on_drug_crime_and_harms.pdf (10 October 2022, date last accessed).

31.

Weatherburn
 
D
,
Jones
 
C
,
Freeman
 
K
,
Makkai
 
T
.
Supply control and harm reduction: lessons from the Australian heroin 'drought'
.
Addiction
 
2003
;
98
(
1
):
83
91
.

32.

Griffiths
 
P
,
Mounteney
 
J
,
Laniel
 
L
.
Understanding changes in heroin availability in Europe over time: emerging evidence for a slide, a squeeze and a shock
.
Addiction
 
2012
;
107
(
9
):
1539
40
.

33.

Cunninham
 
JK
,
Callaghan
 
RC
,
Liu
 
L-M
.
US federal cocaine essential ('precursor') chemical regulation impacts on US cocaine availability: an intervention time-series analysis with temporal replication
.
Addiction
 
2015
;
110
(
5
):
805
20
.

34.

United Nations Office on Drugs and Crime
.
Global Overview: Drug Demand Drug Supply
.
2021
. https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_2.pdf (
13 April 2022, date last accessed
).

35.

Groshkova
 
T
,
Cunningham
 
A
,
Royuela
 
L
 et al.  
Drug affordability–potential tool for comparing illicit drug markets
.
Int J Drug Policy
 
2018
;
56
:
187
96
.

36.

Harris
 
M
,
Forseth
 
K
,
Rhodes
 
T
.
"It's Russian roulette": adulteration, adverse effects and drug use transitions during the 2010/2011 United Kingdom heroin shortage
.
Int J Drug Policy
 
2015
;
26
(
1
):
51
8
.

37.

Kesten
 
JM
,
Holland
 
A
,
Linton
 
M-J
 et al.  
Living Under Coronavirus and Injecting Drugs in Bristol (LUCID-B): A qualitative study of experiences of COVID-19 among people who inject drugs
.
Int J Drug Policy
 
2021
;
98
:
103391
.

38.

Matheson
 
C
,
Parkes
 
T
,
Schofield
 
J
, et al.  
Understanding the health impacts of the COVID-19 response on people who use drugs in Scotland (PWUD)
.
2020
. https://www.cso.scot.nhs.uk/wp-content/uploads/COVSTG2010-1.pdf (
28 March 2022, date last accessed
).

39.

Pascoe
 
M
,
Radley
 
S
,
Simmons
 
HTD
,
Measham
 
F
.
The Cathinone Hydra: Increased Cathinone and caffeine adulteration in the English MDMA market after Brexit and COVID-19 lockdowns
.
Drug Science, policy and Law
 
2022
;
8
.

40.

Spicer
 
J
,
Moyle
 
L
,
Coomber
 
R
.
The variable and evolving nature of ‘cuckooing’ as a form of criminal exploitation in street level drug markets
.
Trends in Organized Crime
 
2020
;
23
:
301
23
.

41.

Stevens
 
A.
 
Applying harm reduction principles to the policing of retail drug markets
.
2013
. https://www.drugsandalcohol.ie/19567/1/MDLE-report-3_Applying-harm-reduction-to-policing-of-retail-markets.pdf (
14 March 2022, date last accessed
).

42.

Waal
 
H
,
Clausen
 
T
,
Gjersing
 
L
,
Gossop
 
M
.
Open drug scenes: responses of five European cities
.
BMC Public Health
 
2014
;
14
(
853
).

43.

Bowlin
 
B
.
Criminal Iatrogenesis
.
Leicester
:
British Society of Criminology
,
2010
.

44.

Curtis
 
R
,
Wendel
 
T
.
“You're Always Training the Dog”: Strategic Interventions to Reconfigure Drug Markets
.
Journal of Drug Issues
 
2007
;
37
(
4
):
867
91
.

45.

Dickenson
 
M
.
The Impact of Leadership Removal on Mexican Drug Trafficking Organizations
.
Journal of Quantitative Criminology
 
2014
;
30
:
651
76
.

46.

Bowling
 
B
. Transnational criminology and the globalization of harm production. In:
Bosworth
 
M
,
Hoyle
 
C
(eds).
What is Criminology
.
Oxford
:
Oxford University Press
,
2011
.

47.

Calderón
 
G
,
Robles
 
G
,
Diaz-Cayeros
 
A
,
Magaloni
 
B
.
The Beheading of Criminal Organizations and the Dynamics of Violence in Mexico
.
J Confl Resolut
 
2015
;
59
(
8
):
1455
85
.

48.

Moeller
 
K
,
Hesse
 
M
.
Drug market disruption and systemic violence: Cannabis markets in Copenhagen
.
European Journal of Criminology
 
2013
;
10
(
2
):
206
21
.

49.

Vargas
 
R
.
Criminal Group Embeddedness and the Adverse Effects of Arresting a Gang’s Leader: A Comparative Case Study
.
Crim
 
2014
;
52
(
2
):
143
68
.

50.

Werb
 
D
,
Rowell
 
G
,
Guyatt
 
G
 et al.  
Effect of drug law enforcement on drug market violence: a systematic review
.
Int J Drug Policy
 
2011
;
22
(
2
):
87
94
.

51.

Bretteville-Jensen
 
AL
,
Mikulic
 
S
,
Bem
 
P
, et al.  
Costs and Unintended Consequences of Drug Control Policies
.
2017
. https://rm.coe.int/costs-and-unitended-consequences-of-drug-control-policies/16807701a9 (
13 April 2022, date last accessed
).

52.

Roscoe
 
S
,
Pryce
 
R
,
Buykx
 
P
 et al.  
Is disinvestment from alcohol and drug treatment services associated with treatment access, completions and related harm? An analysis of English expenditure and outcomes data
.
Drug Alcohol Rev
 
2022
;
41
(
1
):
54
61
.

53.

Office for Health Improvement & Disparities
.
Adult substance misuse treatment statistics 2020 to 2021: report
.
2022
. https://www.gov.uk/government/statistics/substance-misuse-treatment-for-adults-statistics-2020-to-2021/adult-substance-misuse-treatment-statistics-2020-to-2021-report (
25 March 2022, date last accessed
).

54.

Day
 
E
,
Mitcheson
 
L
.
Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism?
 
Addiction
 
2017
;
112
:
1329
36
.

55.

Home Office and Department of Health & Social Care
.
UK Government Recovery Champion Annual Report
.
2021
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/956729/Recovery_Champion_First_Annual_Report.pdf (
30 April 2022, date last accessed
).

56.

Santo
 
T
 Jr,
Clark
 
B
,
Hickman
 
M
 et al.  
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis
.
JAMA Psychiat
 
2021
;
78
(
9
):
979
93
.

57.

Padmanathan
 
P
,
Forbes
 
H
,
Redaniel
 
MT
 et al.  
Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study
.
Lancet Psychiatry
 
2022
;
9
(
2
):
151
9
.

58.

Hickman
 
M
,
Steer
 
C
,
Tilling
 
K
 et al.  
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom
.
Addiction
 
2018
;
113
(
8
):
1461
76
.

59.

Pierce
 
M
,
Bird
 
SM
,
Hickman
 
M
 et al.  
Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England
.
Addiction
 
2016
;
111
(
2
):
298
308
.

60.

Platt
 
L
,
Minozzi
 
S
,
Reed
 
J
 et al.  
Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis
.
Addiction
 
2018
;
113
(
3
):
545
63
.

61.

Cornish
 
R
,
Macleod
 
J
,
Strang
 
J
 et al.  
Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database
.
BMJ
 
2010
;
341
:
c5475
.

62.

Kimber
 
J
,
Copeland
 
L
,
Hickman
 
M
 et al.  
Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment
.
BMJ
 
2010
;
341
:
c3172
.

63.

Nosyk
 
B
,
Anglin
 
MD
,
Brecht
 
M-L
 et al.  
Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study
.
Am J Epidemiol
 
2013
;
117
(
7
):
675
82
.

64.

Hser
 
Y-I
,
Hoffman
 
V
,
Grella
 
CE
,
Anglin
 
MD
.
A 33-year follow-up of narcotics addicts
.
Arch Gen Psychiatry
 
2001
;
58
:
503
8
.

65.

Termorshuizen
 
F
,
Krol
 
A
,
Prins
 
M
 et al.  
Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users
.
Drug Alcohol Depend
 
2005
;
79
(
2
):
231
40
.

66.

Stone
 
J
,
Degenhardt
 
L
,
Grebely
 
J
 et al.  
Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
.
Lancet Psychiatry
 
2021
;
8
(
4
):
301
9
.

67.

Irvine
 
MA
,
Kuo
 
M
,
Buxton
 
JA
 et al.  
Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic
.
Addiction
 
2019
;
114
(
9
):
1602
13
.

68.

Chaillon
 
A
,
Bharat
 
C
,
Stone
 
J
 et al.  
Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales
.
Australia Addiction
 
2022
;
117
(
5
):
1338
52
.

69.

Strang
 
J
,
Groshkova
 
T
,
Uchtenhagen
 
A
 et al.  
Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction
.
Br J Psychiatry
 
2018
;
207
(
1
):
5
14
.

70.

Kilmer
 
B
,
Taylor
 
J
,
Caulkins
 
JP
, et al.  
Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States
.
2018
. https://www.rand.org/pubs/research_reports/RR2693.html (
19 April 2022, date last accessed
).

71.

Maghsoudi
 
N
,
Tanguay
 
J
,
Scarfone
 
K
 et al.  
Drug checking services for people who use drugs: a systematic review
.
Addiction
 
2021
;
117
(
3
):
532
44
.

72.

Measham
 
F
,
Turnbull
 
G
,
Turnbull
 
G
.
Intentions, actions and outcomes: A follow up survey on harm reduction practices after using an English festival drug checking service
.
Int J Drug Policy
 
2021
;
95
:
103270
.

73.

European Monitoring Centre for Drugs and Drug Addiction
.
EMCDDA Insights - New heroin-assisted treatment
.
2012
. https://www.emcdda.europa.eu/system/files/publications/690/Heroin_Insight_335259.pdf (
22 February 2022, date last accessed
).

74.

Bushby
 
M
,
Ellson
 
A
.
First licence for service to test purity of illegal drugs
.
The Times
 
2022
. https://www.thetimes.co.uk/article/first-licence-for-service-to-test-purity-of-illegal-drugs-9fsdzs7p2  
24 May 2022, date last accessed
.

75.

UK Health Security Agency
.
Hepatitis C in England 2022 - Working to eliminate hepatitis C as a public health problem
.
2022
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057271/HCV-in-England-2022-full-report.pdf (
22 April 2022, date last accessed
).

76.

Ragonnet-Cronin
 
M
,
Jackson
 
C
,
Bradley-Stewart
 
A
 et al.  
Recent and Rapid Transmission of HIV Among People Who Inject Drugs in Scotland Revealed Through Phylogenetic Analysis
.
J Infect Dis
 
2018
;
217
(
12
):
1875
82
.

77.

Harris
 
RJ
,
Harris
 
HE
,
Mandal
 
S
 et al.  
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data
.
J Viral Hepat
 
2019
;
26
(
5
):
541
51
.

78.

Bardsley
 
M
,
Heinsbroek
 
E
,
Harris
 
R
 et al.  
The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018
.
J Viral Hepat
 
2021
;
28
(
10
):
1452
63
.

79.

Byrne
 
CJ
,
Beer
 
L
,
Inglis
 
SK
 et al.  
Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland
.
Alimentary Pharmacology and Therapeutics
 
2021
;
55
(
5
):
568
79
.

80.

Palmateer
 
NE
,
McAuley
 
A
,
Dillon
 
JF
 et al.  
Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data
.
Addiction
 
2021
;
116
(
10
):
2893
907
.

81.

Yeung
 
A
,
Palmateer
 
NE
,
Dillon
 
JF
 et al.  
Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
.
J Hepatol
 
2022
;
76
(
3
):
549
57
.

82.

Larney
 
S
,
Thi Tran
 
L
,
Leung
 
J
.
All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids
.
JAMA Psychiat
 
2020
;
77
(
5
):
493
502
.

83.

Ferrari
 
AJ
,
Norman
 
RE
,
Freedman
 
G
 et al.  
The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010
.
PLoS One
 
2014
;
9
(
4
).

84.

Lewer
 
D
,
Eastwood
 
B
,
White
 
M
 et al.  
Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study
.
PLoS Med
 
2021
;
18
(
10
).

85.

Muncan
 
B
,
Walters
 
SM
,
Ezell
 
J
,
Ompad
 
DC
.
“They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City
.
Harm Reduct J
 
2020
;
17
(
1
):
53
.

86.

van
 
Boekel
 
LC
,
Brouwers
 
EPM
,
van
 
Weeghel
 
J
,
Garretsen
 
HFL
.
Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review
.
Drug Alcohol Depend
 
2013
;
131
(
1-2
):
23
35
.

87.

Harris
 
M
.
Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care
.
Soc Sci Med
 
2020
;
260
:
113183
.

88.

Harris
 
M
,
Holland
 
A
,
Lewer
 
D
 et al.  
Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies on the management of substance dependence
.
BMC Med
 
2022
;
20
:
151
.

89.

Binswanger
 
IA
,
Stern
 
MF
,
Deyo
 
RA
 et al.  
Release from Prison — A High Risk of Death for Former Inmates
.
N Engl J Med
 
2007
;
356
:
157
65
.

90.

Seaman
 
SR
,
Brettle
 
RP
,
Gore
 
SM
.
Mortality from overdose among injecting drug users recently released from prison: database linkage study
.
BMJ
 
1998
;
316
(
7129
):
426
8
.

91.

Zlodre
 
J
,
Fazel
 
S
.
All-cause and external mortality in released prisoners: systematic review and meta-analysis
.
Am J Public Health
 
2012
;
102
(
12
):
67
75
.

92.

Durjava
 
L
.
Effectiveness of prison-based opioid substitution treatment: a systematic review
.
MOJ Addiction Medicine & Therapy
 
2018
;
5
(
4
):
176
85
.

93.

Marsden
 
J
,
Stillwel
 
G
,
Jones
 
H
 et al.  
Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England
.
Addiction
 
2017
;
112
(
8
):
1408
18
.

94.

HM Inspectorate of Prisons
.
Changing patterns of substance misuse in adult prisons and service responses
.
2015
. https://www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2015/12/Substance-misuse-web-2015.pdf (
17 March 2022, date last accessed
).

95.

Lloyd
 
C
,
McKeganey
 
N
,
Liebling
 
A
.
The Evaluation of the Drug Recovery Wing Pilots
.
2017
. https://www.york.ac.uk/media/healthsciences/documents/research/mentalhealthresearch/DRWsFinalPublishedReport.pdf (
accesed 22 Apr 2022
).

96.

Advisory Council on the Misuse of Drugs
.
Custody-Community Transitions
.
2019
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/902762/CMD_Custody_community_transitions_report_June_2019.pdf (
22 April 2022, date last accessed
).

97.

Gabri
 
AC
,
Galanti
 
MR
,
Orsini
 
N
,
Magnusson
 
C
.
Changes in cannabis policy and prevalence of recreational cannabis use among adolescents and young adults in Europe—An interrupted time-series analysis
.
PLoS One
 
2022
;
17
(
1
):
e0261885
.

98.

Stevens
 
A
.
Is policy 'liberalization' associated with higher odds of adolescent cannabis use? A re-analysis of data from 38 countries
.
Int J Drug Policy
 
2020
;
66
:
94
9
.

99.

Hughes
 
B
,
Matias
 
J
,
Griffiths
 
P
.
Inconsistencies in the assumptions linking punitive sanctions and use of cannabis and new psychoactive substances in Europe
.
Addiction
 
2018
;
113
(
12
):
2155
7
.

100.

Scheim
 
AI
,
Maghsoudi
 
N
,
Marshall
 
Z
 et al.  
Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review
.
BMJ Open
 
2020
;
10
(
9
):
e035148
.

101.

Eastwood
 
N
,
Fox
 
E
,
Rosmarin
 
A
.
A Quiet Revolution: Drug Decriminalisation Across the Globe
.
2016
. https://www.release.org.uk/sites/default/files/pdf/publications/A%20Quiet%20Revolution%20-%20Decriminalisation%20Across%20the%20Globe.pdf  
(27 May 2022, date last accessed)
.

102.
103.

Revolving Doors Agency
.
Balancing Act - Addressing health inequalities among people in contact with the criminal justice system
.  
2013
. https://revolving-doors.org.uk/publications/balancing-act/ (
28 May 2022, date last accessed
).

104.

UK Drug Policy Commission
.
Getting Serious about Stigma:: the problem with stigmatising drug users
.
2010
. https://www.ukdpc.org.uk/wp-content/uploads/Policy%20report%20-%20Getting%20serious%20about%20stigma_%20the%20problem%20with%20stigmatising%20drug%20users.pdf (
19 April 2022, date last accessed
).

105.

Lösel
 
FA
,
Koehler
 
JA
,
Hamilton
 
L
,
Humphreys
 
DK
,
Akoensi
 
TD
.
Strengthening Transnational Approaches to Reducing Reoffending - Final Report
.
2018
. https://www.cep-probation.org/wp-content/uploads/2018/10/STARR-final-report.pdf  
(22 March 2022, date last accessed)
.

106.

Holloway
 
K
,
Bennett
 
T
,
Farrington
 
D
.
The effectiveness of criminal justice and treatment programmes in reducing drug-related crime: a systematic review
.
2005
. https://www.crim.cam.ac.uk/sites/www.crim.cam.ac.uk/files/olr2605.pdf (
22 March 2022, date last accessed
).

107.

Harvey
 
E
,
Shakeshaft
 
A
,
Hetherington
 
K
 et al.  
The efficacy of diversion and aftercare strategies for adult drug-involved offenders: a summary and methodological review of the outcome literature
.
Drug Alcohol Rev
 
2007
;
26
(
4
):
379
87
.

108.

Stevens
 
A
,
Hughes
 
CE
,
Hulme
 
S
,
Cassidy
 
R
.
Depenalization, diversion and decriminalization: A realist review and programme theory of alternatives to criminalization for simple drug possession
.
European Journal of Criminology
 
2019
;
19
(
1
):
29
54
.

109.

European Monitoring Centre for Drugs and Drug Addiction
.
Alternatives to punishment for drug-using offenders
.
2015
. https://www.emcdda.europa.eu/system/files/publications/1020/TDAU14007ENN.pdf (
14 April 2022, date last accessed
).

110.
111.

Stevens
 
A
.
The Ethics and Effectiveness of Coerced Treatment of People Who Use Drugs
.
Human Rights and Drugs
 
2012
;
2
(
1
):
1
.

112.

Werb
 
D
,
Kamarulzaman
 
A
,
Meacham
 
MC
 et al.  
The effectiveness of compulsory drug treatment: A systematic review
.
The International Journal of Drug Policy
 
2016
;
28
:
1
9
.

113.

Shiner
 
M
,
Carre
 
Z
,
Delsol
 
R
,
Eastwood
 
N
.
The Colour of Injustice: 'Race', drugs and law enforcement in England and Wales
.
2018
. https://www.release.org.uk/sites/default/files/pdf/publications/The%20Colour%20of%20Injustice.pdf  
(15 March 2022)
.

114.

HM Government
.
Levelling Up: Levelling Up the United Kingdom
.
2022
. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1052706/Levelling_Up_WP_HRES.pdf (
9 August 2022, date last accessed
).

115.

Csete
 
J
,
Kamarulzaman
 
A
,
Kazatchkine
 
M
 et al.  
Public health and international drug policy
.
The Lancet
 
2016
;
387
(
10026
):
1427
80
.

116.

Kincová
 
E
,
Rolles
 
S
.
The Misuse of Drugs Act 1971: Counting the Costs
.
2022
. https://transformdrugs.org/assets/files/PDFs/Misuse-of-Drugs-Act-Briefing.pdf (
15 March 2022, date last accessed
).

117.

House of Commons Health and Social Care Committee on Drugs Policy
.
2019
. https://publications.parliament.uk/pa/cm201919/cmselect/cmhealth/143/143.pdf (
29 December 2021, date last accessed
).

118.

Royal College of Physicians
.
RCP supports Royal Society for Public Health report on drug policy
.
2018
. https://www.rcplondon.ac.uk/news/rcp-supports-royal-society-public-health-report-drug-policy (
22 March 2022, date last accessed
).

119.

Royal Society for Public Health and the Faculty of Public Health
.
Taking a new line on drugs
.
2016
. https://www.rsph.org.uk/uploads/assets/uploaded/68d93cdc-292c-4a7b-babfc0a8ee252bc0.pdf (
22 February 2022, date last accessed
).

120.

Holland
 
A
,
Harris
 
M
,
Hickman
 
M
 et al.  
Overdose prevention centres in the UK
.
Lancet Public Health
 
2022
;
7
(
3
):
e196
7
.

121.

Shorter
 
GW
,
Harris
 
M
,
McAuley
 
A
 et al.  
The United Kingdom's first unsanctioned overdose prevention site; A proof-of-concept evaluation
.
Int J Drug Policy
 
2022
;
104
:
103670
.

122.

Faculty of Public Health
.
FPH lead cross-sector call to pilot Overdose Prevention Centres in the UK
.
2021
. https://www.fph.org.uk/news-events/fph-news/fph-lead-cross-sector-call-to-pilot-overdose-prevention-centres-in-the-uk/ (
29 December 2021, date last accessed
).

123.

Faculty of Public Health
.
Call to amend Misuse of Drugs Regulations to make it easier to pilot overdose prevention centres
.
2022
. https://www.fph.org.uk/news-events/fph-news/call-to-amend-misuse-of-drugs-regulations-to-make-it-easier-to-pilot-overdose-prevention-centres/ (
9 August 2022, date last accessed
).

124.

Scottish Drug Deaths Taskforce
.
Report on Drug Law Reform
.
2021
. https://drugdeathstaskforce.scot/media/1248/drug-law-reform-report-sept-6th-21.pdf (
21 October 2021, date last accessed
).

125.

Fortson
 
R
,
McCulloch
 
L
.
Evidence and Issues concerning Drug Consumption Rooms
.
Queen Mary University of London
:
School of Law
,
2018
.

126.

Harris
 
M
.
An urgent impetus for action: safe inhalation interventions to reduce COVID19 transmission and fatality risk among people who smoke crack cocaine in the United Kingdom
.
Int J Drug Policy
 
2020
;
83
:
102829
.

127.

Prangnell
 
A
,
Dong
 
H
,
Daly
 
P
 et al.  
Declining rates of health problems associated with crack smoking during the expansion of crack pipe distribution in Vancouver, Canada
.
BMC Public Health
 
2017
;
17
:
163
.

128.

NHS Health Research Authority
.
Public Involvement
.
2022
. https://www.hra.nhs.uk/planning-and-improving-research/best-practice/public-involvement/ (
17 February 2022, date last accessed
).

129.

NHS England
.
Patient and Public Participation Policy
.
2017
. https://www.england.nhs.uk/wp-content/uploads/2017/04/ppp-policy.pdf (
17 February 2022, date last accessed
)

130.

Canadian HIV/AIDS Legal Network, International HIV/AIDS Alliance, Open Society Institute
.
``Nothing About Us Without Us'' - Greater, Meaningful Involvement of People Who Use Illegal Drugs: A Public Health, Ethical and Human Rights Imperative - International Edition
.
2008
. https://www.opensocietyfoundations.org/publications/nothing-about-us-without-us (
17 February 2022, date last accessed
).

131.

Ti
 
L
,
Tzemis
 
D
,
Buxton
 
JA
.
Engaging people who use drugs in policy and program development: A review of the literature
.
Subst Abuse Treat Prev Policy
 
2012
;
7
(
47
).

132.

International Network of People Who Use Drugs
.
Drug War Peace
.
2014
. https://www.unodc.org/documents/ungass2016/Contributions/Civil/INPUD/DUPI-Violations_of_the_Human_Rights_of_People_Who_Use_Drugs-Web.pdf (
17 March 2022, date last accessed
).

133.

United Nations Development Programme
.
International Guidelines on Human Rights and Drug Policy
.
2019
. https://www.undp.org/publications/international-guidelines-human-rights-and-drug-policy (
17 March 2022, date last accessed
).

134.

Jürgens
 
R
,
Csete
 
J
,
Amon
 
JJ
 et al.  
People who use drugs, HIV, and human rights
.
Lancet
 
2010
;
376
(
9739
):
475
85
.

135.

The Asian Network of People who use Drugs and the International Network of People who use Drugs
.
WORDS MATTER! Language Statement & Reference Guide
.
2020
. https://www.inpud.net/sites/default/files/000596_INP_Terminology%20booklet_v11.pdf (
12 February 2022, date last accessed
).

136.

UK Government
.
Problem drug use in Scotland: Government response to the Committee’s First Report of Session 2019
.
2020
. https://publications.parliament.uk/pa/cm5801/cmselect/cmscotaf/698/69802.htm (
19 April 2022, date last accessed
).

137.

Scottish Drug Deaths Taskforce
.
A Strategy to Address the Stigmatisation of People and Communities Affected by Drug Use
.
2020
. https://drugdeathstaskforce.scot/media/1111/stigma-strategy-for-ddtf-final-290720.pdf (
22 February 2022, date last accessed
).

138.

NHS Addictions Provider Alliance
.
Stigma Kills
.
2022
. https://www.nhsapa.org/_files/ugd/d8f2eb_f884f11c3bfe4821abbbc758cc83d7de.pdf (
22 February 2022, date last accessed
).

139.

Lancaster
 
K
,
Seear
 
K
,
Ritter
 
A
.
Reducing stigma and discrimination for people experiencing problematic alcohol and other drug use
.
2017
. https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Reducing%20stigma%20and%20discrimination%20for%20people%20experiencing%20problematic%20alcohol%20and%20other%20drug%20use.pdf (
19 April 2022, date last accessed
).

140.

Strangl
 
AL
,
Earnshaw
 
VA
,
Logie
 
CH
 et al.  
The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas
.
BMC Med
 
2019
;
17
.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.